Mitsu Chem Plast publishes Q1FY27 results; net profit up 566% to ₹8.74 crore
Mitsu Chem Plast Limited published its Q1FY27 results on August 15, 2026, reporting a 566% YoY net profit surge to ₹8.74 crore. Revenue grew 11.62% to ₹95.33 crore, while EBITDA margins expanded significantly to 16.29%. The company also detailed a preferential issue of warrants for capacity expansion.

*this image is generated using AI for illustrative purposes only.
Mitsu Chem Plast Limited published its financial results for the quarter ended June 30, 2026, in newspapers on August 15, 2026. The company confirmed a sharp acceleration in profitability, with net profit surging 566% year-on-year to ₹8.74 crore. Total income rose 11.62% to ₹95.33 crore for the period.
The disclosure was made in compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The advertisements appeared in Financial Express (all editions) and Mumbai Lakshadeep.
Financial Performance
The operating performance improved markedly, with EBITDA jumping 209.50% to ₹15.49 crore. This growth outpaced revenue expansion, driving the EBITDA margin up by 1,041 basis points to 16.29%, compared to 5.87% in the corresponding period of the previous fiscal year.
| Metric | Q1FY27 (₹ Lakh) | Q1FY26 (₹ Lakh) | YoY Change |
|---|---|---|---|
| Total Income | 9,532.78 | 8,540.39 | +11.62% |
| EBITDA | 1,549.48 | 500.64 | +209.50% |
| EBITDA Margin | 16.29% | 5.87% | +1,041 bps |
| Net Profit | 873.83 | 131.16 | +566.23% |
| Net Profit Margin | 9.18% | 1.54% | +765 bps |
| EPS (₹) | 6.44 | 0.97 | +563.92% |
What the Numbers Show
The divergence between revenue growth and profit expansion highlights a significant operational leverage effect. While top-line revenue grew by a modest 11.62%, net profit increased by more than five times that rate (566%). This suggests that fixed costs were absorbed more efficiently or that the product mix shifted toward higher-margin segments, allowing the company to convert a larger portion of incremental revenue directly into bottom-line earnings. The EBITDA margin more than doubled, reinforcing the view that the profit surge was driven by core operational improvements rather than one-off items.
Preferential Issue and Capacity Expansion
Alongside the financial results, the company announced a proposed preferential issue of 10 lakh convertible warrants. The allottees include promoters Mr. Manish Dedhia (4.75 lakh warrants) and Mr. Sanjay Dedhia (3.25 lakh warrants), along with non-promoter Rikhav Securities Limited (2 lakh warrants).
Upon completion, the aggregate promoter shareholding is expected to increase from 67.77% to 68.61% on a fully diluted basis. Individually, Mr. Sanjay Dedhia’s holding will rise from 9.37% to 10.95%, while Mr. Manish Dedhia’s will increase from 12.34% to 14.75%.
The funds raised are intended to support growth and expansion plans, including a proposed addition of 3,550 metric tons per annum to its existing manufacturing capacity of over 32,450 metric tons per annum. The company noted that existing capacity utilization stood at 64% in FY26.
Management Commentary
Sanjay Dedhia, Executive Vice Chairman, stated that the quarter reflected continued progress in strengthening manufacturing capabilities across the diversified product portfolio. He emphasized that the capacity expansion would help cater to growing demand in key segments such as industrial packaging, healthcare products, and infrastructure solutions.
Mitsu Chem Plast serves original equipment manufacturers across sectors including chemicals, pharmaceuticals, and hospital furniture. In FY26, the company reported total income of ₹350.85 crore, with an EBITDA of ₹34.66 crore and a net profit of ₹15.62 crore.
Historical Stock Returns for Mitsu Chem Plast
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.86% | -0.08% | +17.35% | +83.31% | +71.00% | -33.78% |
How will the addition of 3,550 metric tons of capacity impact Mitsu Chem Plast's current 64% utilization rate and overall margin sustainability in FY27?
What specific cost-saving measures or product mix shifts drove the 1,041 basis point expansion in EBITDA margins despite only modest revenue growth?
Will the preferential issue of convertible warrants lead to immediate dilution for existing shareholders, or will the promoters' increased stake offset this effect?


































